The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Seed Amplification Assay Innovation Program, 2025Quantitative Real-Time Alpha-synuclein Seed Detection by SeRAS®
Study Rationale: Seed Amplification Assays (SAAs) can detect minute amounts of alpha-synuclein deposits (called seeds) in cerebrospinal fluid (CSF) and other biofluids of Parkinson’s patients. They...
-
Seed Amplification Assay Innovation Program, 2025Quantification of Seed Competent Alpha-synuclein in Body Fluids
Study Rationale: Seed amplification assays (SAA) are very effective in helping to diagnose Parkinson’s where the alpha-synuclein protein is involved. Using “spinal tap” fluid (CSF), SAA can tell if a...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2025CT600 as a Neuroprotective Peptide Therapeutic for Parkinson’s Disease
Study Rationale: Excess CDK5 protein kinase activity in the brain caused by the binding of CDK5 with another protein called P25 has been connected to Parkinson's disease. The CDK5-P25 interaction can...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2025Neuroprotective Therapy for PD Using Stabilizers of the LRRK2:14-3-3 Interaction, Supplement
Study Rationale: Our previous work shows that regulation of the phosphorylation of the Parkinson’s disease protein ‘leucine-rich repeat kinase 2’ (LRRK2) is a key mechanism controlling LRRK2...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2025Assessing Pre-clinical Efficacy of Brain-penetrant TRPML1 Agonists to Treat Parkinson’s Disease
Study Rationale: Parkinson’s disease (PD) is characterized by the accumulation of misfolded and aggregated alpha-synuclein inside neurons in the brain. This may either arise from, or be exacerbated by...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2025ACT-02 as a Disease-modifying Therapy for Parkinson’s
Study Rationale: Parkinson’s disease (PD) is a complex neurodegenerative disorder marked by the loss of dopaminergic neurons, however the underlying exact reasons are still not fully understood...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.